GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.66
+9.45%Year over year
Reported trailing growth
- Revenue
- -83.9%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +27.6%
- EBITDA
- -14.5%
- EPS
- +0.4%
Three-year CAGR
- Revenue
- +63.5%
- EBITDA
- +49.4%
- EBIT
- +33.2%
- Net income
- +46.9%
- EPS
- +39.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026